Patient Leaflet Updated 28-May-2026 | Janssen-Cilag Ltd (a Johnson & Johnson Company)
Byannli 700mg and 1000mg prolonged-release suspension for injection in pre-filled syringe
BYANNLI 700 mg prolonged-release suspension for injection in pre-filled syringe
BYANNLI 1000 mg prolonged-release suspension for injection in pre-filled syringe
paliperidone
1. What BYANNLI is and what it is used for
2. What you need to know before you use BYANNLI
3. How to use BYANNLI
4. Possible side effects
5. How to store BYANNLI
6. Contents of the pack and other information
BYANNLI contains the active substance paliperidone which belongs to the class of antipsychotic medicines.
BYANNLI is used as a maintenance treatment for the symptoms of schizophrenia in adult patients.
If you have responded well to treatment with paliperidone palmitate injection given once a month or once every three months, your doctor may start treatment with BYANNLI.
Schizophrenia is a disease with “positive” and “negative” symptoms. Positive means an excess of symptoms that are not normally present. For example, a person with schizophrenia may hear voices or see things that are not there (called hallucinations), believe things that are not true (called delusions), or feel unusually suspicious of others. Negative means a lack of behaviours or feelings that are normally present. For example, a person with schizophrenia may appear withdrawn and may not respond at all emotionally or may have trouble speaking in a clear and logical way. People with this disease may also feel depressed, anxious, guilty, or tense.
BYANNLI can help alleviate the symptoms of your disease and reduce the risk of your symptoms coming back.
Talk to your doctor, pharmacist or nurse before using BYANNLI.
This medicine has not been studied in elderly patients with dementia. However, elderly patients with dementia, who are treated with other similar types of medicine, may have an increased risk of stroke or death (see section 4).
All medicines have side effects and some of the side effects of this medicine can worsen the symptoms of other medical conditions. For that reason, it is important to discuss with your doctor any of the following conditions which can potentially worsen during treatment with this medicine:
If you have any of these conditions, please talk to your doctor as he/she may want to adjust your dose or monitor you for a while.
As dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood has been seen very rarely with patients taking this medicine, your doctor may check your white blood cell counts.
Even if you have previously tolerated oral paliperidone or risperidone, rarely allergic reactions occur after receiving injections of BYANNLI. Seek medical attention right away if you experience a rash, swelling of your throat, itching, or problems breathing as these may be signs of a serious allergic reaction.
This medicine may cause you to gain or loose weight. Significant changes in weight may be bad for your health. Your doctor should regularly measure your body weight.
As diabetes mellitus or worsening of pre-existing diabetes mellitus have been seen with patients taking this medicine, your doctor should check for signs of high blood sugar. In patients with pre-existing diabetes mellitus blood glucose should be monitored regularly.
Since this medicine may reduce your urge to vomit, there is a chance that it may mask the body’s normal response to ingestion of toxic substances or other medical conditions.
If you are planning to have an operation on your eye, make sure you tell your eye doctor that you are taking this medicine. This is because during a cataract operation on the eye for cloudiness of the lens:
Do not use this medicine in children and adolescents under 18 years of age. It is not known if it is safe and effective in these patients.
Tell your doctor if you are taking, have recently taken or might take any other medicines.
Taking this medicine with carbamazepine (an anti-epileptic and mood stabiliser) may require a change to your dose of this medicine.
Since this medicine works primarily in the brain, using other medicines that work in the brain can cause an exaggeration of side effects such as sleepiness or other effects on the brain such as other psychiatric medicines, opioids, antihistamines and sleep medicines.
Tell your doctor if you take this medicine while you are also taking oral risperidone or paliperidone for extended periods of time. You may require a change to your dose of BYANNLI.
Since this medicine can lower blood pressure, care should be taken when this medicine is used with other medicines that lower blood pressure.
This medicine can reduce the effect of medicines against Parkinson’s disease and restless legs syndrome (e.g., levodopa).
This medicine may cause an electrocardiogram (ECG) abnormality demonstrating a long time for an electrical impulse to travel through a certain part of the heart (known as “QT prolongation”). Other medicines that have this effect include some medicines used to treat the rhythm of the heart or to treat infection, and other antipsychotics.
If you have a history of seizures, this medicine may increase your risk of experiencing them. Other medicines that have this effect include some medicines used to treat depression or to treat infection, and other antipsychotics.
BYANNLI should be used with caution with medicines that increase the activity of the central nervous system (psychostimulants such as methylphenidate).
Alcohol should be avoided.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Women of childbearing potential
A single dose of this medicine is expected to remain within the body for up to 4 years, which may be a risk for the baby. BYANNLI should, therefore, only be used in women planning to have a baby if clearly necessary.
Pregnancy
You should not use this medicine during pregnancy unless this has been discussed with your doctor. The following symptoms may occur in newborn babies of mothers that have used paliperidone in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. Newborns should be monitored carefully and if your baby develops any of these symptoms seek medical attention for your baby.
Breast-feeding
This medicine can pass from mother to baby through breast milk. It may harm the baby, even a long time after the latest dose. Therefore, you should not breast-feed if you are using, or have used, this medicine in the past 4 years.
Dizziness, extreme tiredness and vision problems may occur during treatment with this medicine (see section 4). This should be considered in cases where full alertness is required, e.g., when driving a car or handling machines.
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium-free”.
This medicine is administered by your doctor or other healthcare professional. Your doctor will tell you when you need your next injection. It is important not to miss your scheduled dose. If you cannot keep your appointment, make sure you call right away so another appointment can be made as soon as possible.
You will receive an injection of BYANNLI in the buttocks once every 6 months.
Depending on your symptoms, your doctor may increase or decrease the amount of medicine you receive at the time of your next scheduled injection.
Patients with kidney problems
If you have mild kidney problems your doctor will determine if BYANNLI is appropriate based on the dose of 1-monthly or 3-monthly paliperidone palmitate injectable that you have been receiving. The 1000 mg dose of BYANNLI is not recommended.
If you have moderate or severe kidney problems this medicine should not be used.
Elderly
Your doctor may adjust your dose of this medicine if your kidney function is reduced.
This medicine will be given to you under medical supervision; it is, therefore, unlikely that you will be given too much.
Patients who have been given too much paliperidone may experience the following symptoms: drowsiness or sedation, fast heart rate, low blood pressure, an abnormal electrocardiogram (electrical tracing of the heart), or slow or abnormal movements of the face, body, arms or legs.
If you stop receiving your injections, your symptoms of schizophrenia may get worse. You should not stop using this medicine unless told to do so by your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you get any of the following serious side effects, you may need immediate medical treatment. Tell your doctor or go to the nearest hospital straight away:
Even if you have previously tolerated oral risperidone or oral paliperidone, rarely allergic reactions occur after receiving injections of paliperidone.
Tell your doctor straight away or go to the nearest hospital immediately if you notice any of the serious side effects above.
Very common side effects: may affect more than 1 in 10 people
Common side effects: may affect up to 1 in 10 people
Uncommon side effects: may affect up to 1 in 100 people
Rare side effects: may affect up to 1 in 1000 people
Not known: frequency cannot be estimated from the available data
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.
This medicine does not require any special temperature storage conditions.
Ship and store in a horizontal position. See arrows on product carton for proper orientation.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
The active substance is paliperidone.
Each BYANNLI 700 mg pre-filled syringe contains 1 092 mg paliperidone palmitate equivalent to 700 mg paliperidone in 3.5 mL.
Each BYANNLI 1000 mg pre-filled syringe contains 1 560 mg paliperidone palmitate equivalent to 1000 mg paliperidone in 5 mL.
The other ingredients are:
Polysorbate 20
Polyethylene glycol 4000
Citric acid monohydrate
Sodium dihydrogen phosphate monohydrate
Sodium hydroxide (for pH adjustment)
Water for injections
BYANNLI is a white to off-white prolonged-release suspension for injection in a pre-filled syringe. pH is approximately 7.0. The doctor or nurse will shake the syringe very fast to resuspend the suspension before it is given as an injection.
Each pack contains 1 pre-filled syringe and 1 needle.
For information in large print, tape, CD or Braille, telephone 0800 7318450.
This leaflet was last revised in April 2026.
50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG
+44 (0) 1494 567 445
+44 (0)1494 567 568
+44 (0)800 731 5550
+44 (0)1494 567 567
https://innovativemedicine.jnj.com/uk/
+44 (0)800 731 8450